Lily L Remsing Rix

Turning liabilities into opportunities: Off-target based drug repurposing in cancer.

Yi Liao, Uwe Rix, Vinayak Palve, 2020, Seminars in cancer biology.

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.

Gerhard Dürnberger, Oliver Hantschel, Giulio Superti-Furga, 2007, Blood.

Polypharmacology-based ceritinib repurposing using integrated functional proteomics.

Bin Fang, Paul A Stewart, Brent M Kuenzi, 2017, Nature chemical biology.